A Review on the Clinical and Pathological Significance of Prorenin Receptor [(P)RR]
Klíčová slova:
Prorenin Receptor, Prorenin, Renin, Handle region PeptideAbstrakt
The (pro)renin receptor (P)RR discovery, which is a novel constituent of Renin Angiotensin-Aldosteron System (RAS) has brought renin and (pro)renin back into spotlight. The (P)RR binds both renin and its inactive precursor (pro)renin, this binding triggers a cascade of intracellular signalling that eventually leads to upregulation of the expression of profibrotic genes, potentially leading to pathogenesis of cardiac and renal fibrosis, growth and remodelling. Clinically, it is also seen that prorenin secreted from the extrarenal tissues like adrenal, ovary, placenta testis, and retina increases 100 folds during diabetes. It has been proved in transgenic animals that the over expression of (P)RR in smooth muscle cells develops hypertension, glomerulosclerosis and kidney damage. Furthermore, the early embryonic lethality seen in (P)RR null mice suggests that (P)RR has additional essential cellular functions. Although, identification of (P)RR has improved our understanding of the physiology of the tissue RAS, its role in pathology is far from clear. Hence (P)RR is a major spotlight in the area of clinical and pathological science, and it can be used for the target oriented drug discovery too. Keywords: Prorenin receptor, prorenin, renin, handle region peptideCite this Article Iswar Hazarika, Anju Das. A Review on the Clinical and Pathological Significance of Prorenin Receptor [(P)RR]. Research & Reviews: Journal of Pharmacology. 2015; 5(2): 11–17p.
Publikováno
Číslo
Sekce
Licence
Declaration and Copyright Transfer Form
(to be completed by authors)
I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.
· I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
· I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
· I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
· I/We also agree to the authorship of the article in the following order:
Author’s name
1. ________________
2. ________________
3. ________________
_______________
We Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal. |
